ZW251 for advanced solid tumors
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial is testing a new drug called ZW251 for people with advanced liver cancer (hepatocellular carcinoma), non-small cell lung cancer, or germ cell tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of either advanced liver cancer, non-small cell lung cancer, or a germ cell tumor (like yolk sac or choriocarcinoma) that has spread or cannot be surgically removed.
- Your tumors can be measured on scans (like CT or MRI).
- You are up and doing daily activities with little or no help (ECOG score 0 or 1).
- Your liver function is stable (Child-Pugh Class A, for liver cancer only).
- Your kidneys, liver, and other organs are working well enough based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MG2512 for people with advanced solid tumors that have not responded to standard treatments or who cannot take standard therapy. The study aims to understand if MG2512 is safe and effective.
This trial tests a combination of two experimental drugs, IMM2510 and IMM27M, for people with advanced hepatocellular carcinoma (a type of liver cancer) that hasn't responded to other treatments. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a new drug, GV20-0251, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and helpful.
This trial tests a new drug called ZL-6201 for people with sarcoma or certain solid tumors that have spread or cannot be removed. It aims to see if the drug is safe and helps shrink tumors.
This trial tests a new drug, RZ-001, combined with valganciclovir, atezolizumab, and bevacizumab for people with hepatocellular carcinoma (a type of liver cancer). The goal is to see if this combination is safe and works better than current treatments.
This study tests an experimental drug (HMPL-A251) for people with advanced solid tumors that have the HER2 protein. It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.